An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.
OBJECTIVE
To assess the efficacy, safety of cefaclor for the treatment of pharyngotonsillitis in Pakistani children.


METHODS
Pakistani children between the ages of two to twelve years and diagnosed with pharyngotonsillitis were eligible to participate in the study. Cefaclor was administered three times daily for a total dose of 20-40 mg/kg/day, depending on the severity of the infection, for 7 days. Patients were evaluated on the basis of symptomatic response and antibiotic susceptibility pattern as a result of bacteriological examination.


RESULTS
Based on observed pre-therapy signs/symptoms of infection with pharyngotonsillitis, 99% of patients (95% CI=94.9% to 100.0%) were reported as having a symptomatic response of Cure or Improvement by end of study. Group A b-haemolytic Streptococci was the most prevalent pathogen isolated pre-therapy (occurring in 45% of patients). Of all patients for whom this pathogen was isolated, 64% had complete eradication by end of therapy, while there was persistence or superinfection in 36% of patients. Only 9 occurrences of non-serious adverse events were observed among 7 of the 107 patients, including diarrhea (5), nausea (1), vomiting (1), rash (1) and stomatitis (1).


CONCLUSIONS
Based on the high symptomatic response rate of 99% and the positive safety data, cefaclor was found to be effective and safe in treating Pakistani children with pharyngotonsillitis.
Siddiqui
S J
SJ
Eli Lilly, Indonesia.
Awan
A
A
Ekangakic
A
A
Stocks
J M
JM
Sheikh
G A
GA
Ahmad
T M
TM
Mian
F A
FA
Kanjee
S
S
Sheikh
S
S
Rashid
A
A
Yousfani
A H
AH
Talat
A
A
Ahmad
M
M
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D015337:Multicenter Studies as Topic; D010612:Pharyngitis / Q000188:drug therapy* / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy*; D013291:Streptococcus / Q000302:isolation & purification; D014069:Tonsillitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002433:Cefaclor